SolarEdge Technologies Files 8-K on Executive and Board Changes

TL;DR

SolarEdge filed an 8-K on Jan 6, 2025, reporting board and exec changes. Watch for details on compensation.

AI Summary

On January 6, 2025, SolarEdge Technologies, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, with a Regulation FD disclosure. Specific details regarding the departures, elections, appointments, and compensatory arrangements are provided within the document.

Why It Matters

This filing signals potential shifts in company leadership and governance, which could impact strategic direction and investor confidence.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with compensation adjustments, can indicate internal shifts that may affect company strategy and performance.

Key Players & Entities

• SOLAREDGE TECHNOLOGIES, INC (company) — Registrant
• January 6, 2025 (date) — Date of earliest event reported
• 1 Hamada Street, Herziliya Pituach, Israel (location) — Principal executive offices address

FAQ

Key Financial Figures

• $0.0001 — ich registered Common stock, par value $0.0001 per share SEDG NASDAQ (Global Selec
• $100 — a Genomics, Inc., provider of the first $100 human genome sequencing solution. Previ
• $195,000 — reflecting the pro rata portion of the $195,000 annual equity award, which will vest in

Filing Documents

• zk2532533.htm (8-K) — 37KB
• exhibit_99-1.htm (EX-99.1) — 9KB
• image00001.jpg (GRAPHIC) — 4KB
• 0001178913-25-000067.txt ( ) — 191KB
• sedg-20250106.xsd (EX-101.SCH) — 4KB
• sedg-20250106_lab.xml (EX-101.LAB) — 21KB
• sedg-20250106_pre.xml (EX-101.PRE) — 16KB
• zk2532533_htm.xml (XML) — 4KB

02 Other Events Departure of

Item 5.02 Other Events Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On January 6, 2025, the Board of Directors (the "Board") of SolarEdge Technologies, Inc. (the "Company") increased the size of the Company's Board from 8 to 10 directors and appointed Mr. Gilad Almogy and Mr. Yoram Teitz to the Board as Class I directors to fill these vacancies, effective immediately, and to serve until the Company's 2025 annual meeting of stockholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal . Mr. Gilad Almogy was also appointed to serve as a member of the Technology Committee. Mr. Yoram Teitz was appointed to serve as the chairman of the Company's Audit Committee, effective immediately. Mr. Gilad Almogy is a founder of and the Chief Executive Officer of Ultima Genomics, Inc., provider of the first $100 human genome sequencing solution. Previously, Mr. Almogy founded and served as the Chief Executive Officer of Cogenra Solar Inc., which he led from inception until its acquisition by SunPower (Nasdaq: SPWR) in 2015. From 1997 to 2009, Mr. Almogy served in a number of roles at Applied Materials Inc. (Nasdaq: AMAT), culminating as a Senior Vice President. Mr. Almogy holds a PhD in Applied Physics from the California Institute of Technology and a BSc in Mathematics and Physics from the Hebrew University in Jerusalem's Talpiot program. Mr. Yoram Teitz is a seasoned financial expert, with over 36 years in the field of public accounting, 15 of which he spent as the Managing Partner of Kost Forer Gabbay & Kasierer, a member of EY Global (EY Israel) from 2007 until 2022. Currently, Mr. Yoram Teitz serves as a senior advisor at General Atlantic LLP., and as the chairman of the Friends of Sheba Medical Center, a non-profit organization. Mr. Yoram Teitz holds a BA in Economics and Accounting from Tel Aviv Universi

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 8, 2025, the Company issued a press release announcing the Board appointments of Messrs. Gilad Almogy and Yoram Teitz. A copy of the press release is attached as Exhibit 99.1 hereto. The information being furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liability of that section, and shall not be incorporated by reference into any other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit Number Description 99.1 Press release, dated January 8, 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SOLAREDGE TECHNOLOGIES, INC. Date: January 8, 2025 By: /s/ Dalia Litay Name: Dalia Litay Title: Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR